Ascendis Pharma A/s

(NASDAQ) ASND

Current Price$238.51

Market Cap$14.65B

Since IPO (2026)-3%

5 Year+80%

1 Year+50%

1 Month+2%

Ascendis Pharma A/s Financials at a Glance

Market Cap

$14.65B

Revenue (TTM)

$717.81M

Net Income (TTM)

$227.72M

EPS (TTM)

$8.87

P/E Ratio

25.39

Dividend

$0.00

Beta (Volatility)

0.73 (Low)

Dividend

$0.00

Beta (Volatility)

0.73 (Low)

Price

$238.51

Volume

674,238.767

Open

$246.14

Price

$238.51

Volume

674,238.767

Open

$246.14

Previous Close

$238.66

Daily Range

$236.22 - $250.27

52-Week Range

$150.89 - $250.74

Dividend

$0.00

Beta (Volatility)

0.73 (Low)

Price

$238.51

Volume

674,238.767

Open

$246.14

Previous Close

$238.66

Daily Range

$236.22 - $250.27

52-Week Range

$150.89 - $250.74

ASND News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ascendis Pharma A/s

Industry

Biotechnology

Sector

Health Care

CEO

Jan Møller Mikkelsen

Website

www.ascendispharma.com

Headquarters

Hellerup, 2900, DK

ASND Financials

Key Financial Metrics (TTM)

Gross Margin

86%

Operating Margin

-19%

Net Income Margin

-32%

Return on Equity

326%

Return on Capital

-59%

Return on Assets

-17%

Earnings Yield

3.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$14.65B

Shares Outstanding

61.38M

Volume

674.24K

Avg. Volume

716.16K

Financials (TTM)

Gross Profit

$588.53M

Operating Income

$130.89M

EBITDA

$113.90M

Operating Cash Flow

$51.77M

Capital Expenditure

$8.15M

Free Cash Flow

$43.62M

Cash & ST Invst.

$615.78M

Total Debt

$871.41M

Ascendis Pharma A/s Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$245.18M

+41.0%

Gross Profit

$217.98M

+36.3%

Gross Margin

88.91%

N/A

Market Cap

$14.65B

N/A

Market Cap/Employee

$14.40M

N/A

Employees

1,017

N/A

Net Income

$33.25M

+13.6%

EBITDA

$14.58M

+138.5%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$255.64M

+13.9%

Accounts Receivable

$157.63M

-5.2%

Inventory

$301.40M

+2.0%

Long Term Debt

$385.09M

+5.5%

Short Term Debt

$486.32M

-1.1%

Return on Assets

-17.49%

N/A

Return on Invested Capital

-58.50%

N/A

Free Cash Flow

$67.37M

+176.9%

Operating Cash Flow

$70.67M

+181.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SMMTSummit Therapeutics Inc.

SMMTSummit Therapeutics Inc.$18.08+5.42%

BBIOBridgeBio Pharma, Inc.

BBIOBridgeBio Pharma, Inc.$67.39-0.09%

GHGuardant Health, Inc.

GHGuardant Health, Inc.$95.70+3.73%

IONSIonis Pharmaceuticals, Inc.

IONSIonis Pharmaceuticals, Inc.$75.71-0.41%

EXELExelixis, Inc.

EXELExelixis, Inc.$48.16+4.22%

MDGLMadrigal Pharmaceuticals, Inc.

MDGLMadrigal Pharmaceuticals, Inc.$510.04-4.64%

BMRNBioMarin Pharmaceutical Inc.

BMRNBioMarin Pharmaceutical Inc.$54.06-0.11%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

RXTRackspace Technology

RXTRackspace Technology$5.49+0.56%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.62+0.08%

NOKNokia

NOKNokia$12.82+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.28+0.07%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.57-0.07%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.35+0.01%

EOSEEos Energy Enterprises

EOSEEos Energy Enterprises$8.01+0.26%

Questions About ASND

What is the current price of Ascendis Pharma A/s?

Ascendis Pharma A/s is trading at $238.66 per share.

What is the 52-week range for Ascendis Pharma A/s?

Over the past 52 weeks, Ascendis Pharma A/s has traded between $150.89 and $250.74.

How much debt does Ascendis Pharma A/s have?

As of the most recent reporting period, Ascendis Pharma A/s reported total debt of $1.03B.

How much cash does Ascendis Pharma A/s have on hand?

Ascendis Pharma A/s reported $660.00M in cash and cash equivalents in its most recent financial results.

What is Ascendis Pharma A/s’s dividend yield?

Ascendis Pharma A/s does not currently have a dividend yield.

Ascendis Pharma A/s

Ascendis Pharma A/s Financials at a Glance

ASND News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Ascendis Pharma A/s

ASND Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Ascendis Pharma A/s Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ASND

What is the current price of Ascendis Pharma A/s?

What is the 52-week range for Ascendis Pharma A/s?

How much debt does Ascendis Pharma A/s have?

How much cash does Ascendis Pharma A/s have on hand?

What is Ascendis Pharma A/s’s dividend yield?

Premium Investing Services